3-Heptanone as a potential new marker for valproic acid therapy

被引：56

作者：

Erhart, S. ^{[1
]}

Amann, A. ^{[4
]}

Haberlandt, E. ^{[1
]}

Edlinger, G. ^{[1
]}

Schmid, A. ^{[2
,4
]}

Filipiak, W. ^{[2
,4
]}

Schwarz, K. ^{[2
,4
]}

Mochalski, P. ^{[2
,3
,4
]}

Rostasy, K. ^{[1
]}

Karall, D. ^{[1
]}

Scholl-Buergi, S. ^{[1
]}

机构：

[1] Innsbruck Med Univ, Dept Pediat Neuropediat & Inherited Metab Disorde, A-6200 Innsbruck, Austria

[2] Med Univ Innsbruck, Dept Anesthesiol & Gen Intens Care, A-6200 Innsbruck, Austria

[3] Inst Nucl Phys PAN, PL-31342 Krakow, Poland

[4] Austrian Acad Sci, Breath Res Unit, A-6850 Dornbirn, Austria

来源：

JOURNAL OF BREATH RESEARCH | 2009年 / 3卷 / 01期

关键词：

BETA-OXIDATION; FATTY-ACID; BREATH GAS; METABOLISM;

D O I：

10.1088/1752-7155/3/1/016004

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Breath gas samples from 27 patients with epilepsy (17 male and 10 female patients; mean age: 9.7 years, median age: 8.2 years, SD: +/- 4.2 years) were screened via proton transfer reaction mass spectrometry. The patients were treated with valproic acid (VPA) therapy, and blood samples for determination of VPA concentrations were surveyed. All patients showed significantly elevated concentrations of 3-heptanone (C(7)H(14)O) in exhaled breath gas (mean: 14.7 ppb, median: 13.8 ppb SD: +/- 5.7 ppb). In human breath, several hundred different volatile organic compounds can be detected. In breath of patients with valproic acid monotherapy, an increased concentration of 3-heptanone was measured. The objective of this study was to investigate if serum VPA concentrations correlate with 3-heptanone concentrations in exhaled breath. In conclusion, 3-heptanone in breath gas is significantly elevated in patients treated with the valproic acid, but does not correlate significantly with the VPA concentrations in serum or the daily dose of this drug.

引用

页数：6

共 17 条

[1] Exhaled breath gas as a biochemical probe during sleep
Amann, A
Telser, S
Hofer, L
Schmid, A
Hinterhuber, H
[J]. BREATH ANALYSIS: FOR CLINICAL DIAGNOSIS AND ATHERAPEUTIC MONITORING, 2005, : 305 - 316
[2] Applications of breath gas analysis in medicine
Amann, A
Poupart, G
Telser, S
Ledochowski, M
Schmid, A
Mechtcheriakov, S
[J]. INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, 2004, 239 (2-3) : 227 - 233
[3] Amann A., 2005, Breath analysis for clinical diagnosis and therapeutic monitoring
[4] URINARY-EXCRETION OF VALPROATE AND SOME METABOLITES IN CHRONICALLY TREATED PATIENTS
DICKINSON, RG
HOOPER, WD
DUNSTAN, PR
EADIE, MJ
[J]. THERAPEUTIC DRUG MONITORING, 1989, 11 (02) : 127 - 133
[5] Acute valproate poisoning - Pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy
Eyer, F
Felgenhauer, N
Gempel, K
Steimer, W
Gerbitz, KD
Zilker, T
[J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (04) : 376 - 380
[6] THE ENZYMATIC BASIS FOR THE METABOLISM AND INHIBITORY EFFECTS OF VALPROIC ACID - DEHYDROGENATION OF VALPROYL-COA BY 2-METHYL-BRANCHED-CHAIN ACYL-COA DEHYDROGENASE
ITO, M
IKEDA, Y
ARNEZ, JG
FINOCCHIARO, G
TANAKA, K
[J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1034 (02) : 213 - 218
[7] Breath gas analysis in patients suffering from propionic acidaemia
Janovsky, U
Scholl-Bürgi, S
Karall, D
Beauchamp, J
Hansel, A
Poupart, G
Schmid, A
Amann, A
[J]. Breath Analysis: for Clinical Diagnosis and ATherapeutic Monitoring, 2005, : 401 - 407
[8] Kostrouchová M, 2007, FOLIA BIOL-PRAGUE, V53, P37
[9] KRAMER G, 2002, VALPROINSAURE
[10] Science review: Carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?
Lheureux, PER
Penaloza, A
Zahir, S
Gris, M
[J]. CRITICAL CARE, 2005, 9 (05): : 431 - 440

← 1 2 →